The Lancet Oncology· Paul W Sperduto, Fasila Johri, Hany Soliman, Evan D Buckley, Kathryn E Marqueen, Enoch Chang, Jing Li, Amandeep Mahal, Rifaquat Rahman, Molly Blau, Jonathan Yang, Luke DelBalzo, Luke R G Pike, Kelsey M Frechette, William G Breen, Nuzha Noorah, G Laura Masucci, Hebah Abudawaba, Uwajachukwumma A Uzomah, John M Buatti, Eugene J Vaios, John P Kirkpatrick, Erik P Sulman, Josiah Nieto, Michelle M Kim, Mia Salans, Steve Braunstein, Sanjay Aneja, Veronica Chiang, Michael K Melton, Drexell H Boggs, Tyler Walburn, Helen A Shih, Julie Xiao, Tugce Kutuk, Rupesh Kotecha, Salah Dajani, Sean Sachdev, Geoffrey Sedor, Tony J C Wang, Yuri Fujii, Kentaro Nishioka, Hidefumi Aoyama, Toshimichi Nakano, Katya Strage, Timothy Waxweiler, Neal Shore, Priscilla K Brastianos, Toni K Choueiri, Minesh P Mehta·· 4 小时前AI 评分38
[研究]肾细胞癌脑转移患者的生存：肾癌分级预后评估（Renal GPA）更新
[Articles] Survival in patients with renal cell carcinoma and brain metastases: an update of the Renal Graded Prognostic Assessment
AI 导读
肾细胞癌脑转移患者的生存较既往队列有所改善，但不同分级预后评估（GPA）评分患者的生存差异较大。更新后的Renal GPA可用于估计生存期和颅内无进展生存期、制定个体化治疗方案，并支持临床试验设计、分层及入组资格优化。
来源：The Lancet Oncology · thelancet.com